ERBB2 and breast carcinoma: Alternatively, her dramatic response could be due to the suppression of the HER2-PARP-NF-kB axis by PARP inhibition that we previously reported, which showed HER2+ breast cancer sensitivity to PARP inhibition independent of DNA repair [14, 48, 49].